Optimising Renal Tumour Management Through Artificial Intelligence Modules

Launched by SHAO PENGFEI · Dec 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how artificial intelligence (AI) can help improve the care of patients with kidney tumors, which can be benign (not cancerous) or malignant (cancerous). The trial aims to see if AI can accurately assess the tumor's characteristics from CT scans, help doctors choose the best surgical approach, and combine CT images with pathology slides to provide better predictions about patient outcomes after surgery.

To be eligible for this study, participants need to have a kidney tumor that can be treated with surgery and must have had a specific type of CT scan within 30 days before the surgery. It’s important that participants understand the study and agree to take part. Those who join will be monitored for five years after surgery to gather information about their recovery and survival. The trial is currently recruiting participants aged 65 to 74, and both men and women can take part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with renal tumor which can be treated by surgery;
• • Complete CECT within 30 days before surgery;
• • Patients who fully understand this study and sign the informed consent;
• Exclusion Criteria:
• • Patients with any item missing from the baseline clinical and pathological information;
• • Patients who has already metastasized by the time the tumor is discovered;
• • Previous treatment in any form, including surgery, targeted therapy and immunotherapy;